Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
RLY-2608 is an inhibitor of PI3Kα containing a histidine-to-arginine mutation at position 1,047 (PI3KαH1047R; IC50 = 4 nM).1 It is selective for PI3KαH1047R over wild-type PI3Kα (IC50 = 48 nM). RLY-2608 (25 and 100 mg/kg) reduces tumor volume in T47D and ST1056 PI3KαH1047R mutant-containing breast cancer mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. Discovery and clinical proof-